EP0804076A1 - Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs - Google Patents

Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs

Info

Publication number
EP0804076A1
EP0804076A1 EP95938753A EP95938753A EP0804076A1 EP 0804076 A1 EP0804076 A1 EP 0804076A1 EP 95938753 A EP95938753 A EP 95938753A EP 95938753 A EP95938753 A EP 95938753A EP 0804076 A1 EP0804076 A1 EP 0804076A1
Authority
EP
European Patent Office
Prior art keywords
vector
administration
cells
administered
adenoviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95938753A
Other languages
German (de)
English (en)
Other versions
EP0804076A4 (fr
Inventor
Bruce C. Trapnell
Soonpin Yei
Alan Mcclelland
Michael Kaleko
Theodore Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Therapy Inc
Original Assignee
Genetic Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Therapy Inc filed Critical Genetic Therapy Inc
Publication of EP0804076A1 publication Critical patent/EP0804076A1/fr
Publication of EP0804076A4 publication Critical patent/EP0804076A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Definitions

  • This invention relates to gene therapy comprising the use of adenoviruses as the gene delivery vehicles. More particularly, this invention relates to gene therapy involving the concurrent and repeated administration of adenoviruses and immunosuppressive agents, whereby the efficiency of the gene therapy treatment is enhanced through suppression of an immune response against the adenoviruses.
  • Adenovirus genomes are linear, double-stranded DNA molecules of approximately 36 kilobase pairs. Each extremity of the viral genome has a short sequence known as the inverted terminal repeat (or ITR) , which is necessary for viral replication.
  • ITR inverted terminal repeat
  • the well-characterized molecular genetics of adenovirus render it an advantageous vector for gene transfer. Portions of the viral genome can be substituted with DNA of foreign origin.
  • recombinant adenoviruses are structurally stable.
  • Adenoviruses can be very efficient in gene transfer into cells in vivo, and, thus may be employed as delivery vehicles for introducing desired genes into eukaryotic cells, whereby the adenovirus delivers such genes to eukaryotic cells by binding cellular receptors.
  • adenovirus gene transfer There are, however, several limitations to adenovirus gene transfer which are due in part to host responses directed at either the adenovirus vector particle, breakdown products of the vector particle, or the transduced cells. These host responses include non-specific responses and specific immune responses. The non-specific responses include inflammatory and non-inflammatory changes. An example of the latter is a change in host cell gene expression.
  • Specific immune responses include various cellular responses and humoral antibody responses. Cellular responses include those mediated by T-helper lymphocytes, T- suppressor lymphocytes, cytotoxic T lymphocytes (CTL) , and nacural killer cells.
  • mice of an adenoviral vector including a human Factor IX gene discloses the administration to mice of an adenoviral vector including a human Factor IX gene. Such administration resulted in efficient liver transduction and plasma levels of human Factor IX that would be therapeutic for hemophilia B patients. Human Factor IX levels, however, slowly declined to baseline by nine weeks after injection, and were not re ⁇ established by a second vector injection. Smith, et al . , also found that neutralizing antibodies to adenovirus block successful repeat administration of the adenovirus.
  • Kozarsky, et al . , J. Biol. Chem.. Vol. 269, No. 18, pgs . 13695-13702 discloses the infusion of an adenoviral vector including DNA encoding the LDL receptor to rabbits . Stable expression of the LDL receptor gene was found in the rabbits for 7 to 10 days, and diminished to undetectable levels within 3 weeks. The development of neutralizing antibodies to the adenovirus resulted in a second dose being completely ineffective.
  • T-cell response contributes to, but is not responsible solely for, the limited duration of expression in adulcs from adenovirus vectors.
  • the authors further show that cyclosporin A is not effective in blocking the humoral response to the vector.
  • adenoviruses in which the Ela and Elb regions have been deleted.
  • viruses also include a transgene .
  • cells harboring the recombinant viral genome express the transgene as desired; however, low level expression of viral genes also occurs.
  • a virus-specific cellular immune response is stimulated that leads to destruction of the genetically modified cells, thereby limiting the duration of expression of the transgene.
  • Figure 1 is a schematic of the construction of plasmid pHR.
  • Figure 2 is a schematic of the construction of an expression vehicle including an adenoviral ITR, an encapsidation signal, a Rous Sarcoma Virus promoter, an adenoviral tripartite leader sequence, and linking sequences;
  • Figure 3 is a schematic of the construction of plasmid pAvS6;
  • Figure 4 is a map of plasmid pAvS6
  • Figure 5 is a map of plasmid pBQ4.7;
  • Figure 6 is a map of plasmid pAvS6 - CFTR;
  • Figure 7 is a schematic of adenoviral vectors AvlLucl and AvlCf2;
  • Figure 8 is a map of plasmid pGEM-luc
  • Figure 9 is a map of plasmid pAVS6-luc
  • Figures 10A, 10B, and IOC depict the histologic appearance of the lung in response to AvlCf2 administration three days after vector administration;
  • Figures 11A and 11B are graphs showing the effect of dexamethasone administration on lung lavage cells at 3 days and 42 days after the administration of AvlCf2;
  • Figure 12 is a graph of anti-adenoviral antibody titers of lung lavage samples from rats infected with AvlCf2 and which were treated or not treated with dexamethasone;
  • Figure 13 is a graph of CTL responses in rats 42 days after infection with AvlCf2;
  • Figure 14 is a graph of luciferase enzyme activity in rats infected with AvlCf2 and which were treated or not treated with dexamethasone, followed by infection with AvlLucl;
  • Figure 15 is a map of plasmid pAvlH9FR
  • Figure 16 is a schematic of the adenoviral vector AV1H9F2
  • Figure 17 is a graph of plasma human Factor IX levels in mice which were given AvlH9F2, and were or were not given one of the immunosuppressive agents deoxyspergualin, cyclophosphamide, or dexamethasone with or without the administration of the vector AvlLacZ4 five weeks earlier;
  • Figure 18 is a graph of plasma Factor IX levels (ng/ l) in mice which received from lxlO 5 to 1x10 s pfu of AvlLacZ4, followed by administration of AvlH9FR five weeks later;
  • Figure 19 is a graph of neutralizing antibody titer in mice that were given AvlLac24, and received no immunosuppression, or were treated with deoxyspergualin, cyclophosphamide, or dexamethasone;
  • Figure 20 is a graph of plasma Factor VIII levels in mice which were given AvlLacZ4, and received no immunosuppression, or were given cyclophosphamide, followed by administration of AvlH9F2 with or without cyclophosphamide, followed by administration of AvlALAPH ⁇ l; and
  • Figure 21 is a graph of plasma Factor IX levels (ng/ml) in mice which received AvlLacZ4 and 0 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, or 33 mg/kg deoxyspergualin, followed by administration of AvlH9F2.
  • a method of effecting a gene therapy treatment in a host comprises administering to a host (i) an adenoviral vector including at least one DNA sequence and (ii) an immunosuppressive agent.
  • the course of administration of the adenoviral vector and immunosuppressive agent then is discontinued.
  • Administration of the immunosuppressive agent and the adenoviral vector then is repeated at least once.
  • the adenoviral vector is administered in an amount effective to produce a therapeutic effect in the host .
  • the immunosuppressive agent is administered in an amount effective to prevent or suppress a humoral and/or cellular immune response to the vector and/or cells containing the vector.
  • DNA sequence refers generally to a polydeoxyribonucleotide molecule and more specifically to a linear series of deoxyribonucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of the adjacent pentoses .
  • Applicants have found that, when an immunosuppressive agent is administered with the adenoviral vector, and then administration of the vector is repeated, one achieves enhanced efficacy of the repeat in vivo adenoviral-mediated gene transfer through suppression of an immune response (such as a humoral antibody response) against the adenoviral vector and/or cells transduced with the vector, and thereby achieves increased expression of the transferred genes.
  • an immunosuppressive agent such as a humoral antibody response
  • the adenoviral vector which is employed may, in one embodiment;, be an adenoviral vector which includes essentially the complete adenoviral genome. Shenk et al . , Curr . Top . Microbiol . Immunol . , Il l (3 ) . - 1 - 39 (1984) . Alternatively, the adenoviral vector may be a modified adenoviral vector in which at least a portion of the adenoviral genome has been deleted.
  • the adenoviral vector comprises an adenoviral 5' ITR; an adenoviral 3' ITR; an adenoviral encapsidation signal; at least one DNA sequence encoding a therapeutic agent; and a promoter controlling the at least one DNA sequence encoding the therapeutic agent.
  • the vector is free of at least the majority of adenoviral El and E3 DNA sequences, but is not free of all of the E2 and E4 DNA sequences, and DNA sequences encoding adenoviral proteins promoted by the adenoviral major late promoter.
  • the vector also is free of at least a portion of at least one DNA sequence selected from the group consisting of the E2 and E4 DNA sequences.
  • the vector is free of at least the majority of the adenoviral El and E3 DNA sequences, and is free of a portion of the other of the E2 and E4 DNA sequences .
  • the gene in the E2a region that encodes the 72 kilodalton binding protein is mutated to produce a temperature sensitive protein that is active at 32°C, the temperature at which the viral particles are produced.
  • This temperature sensitive mutant is described in Ensinger et al . , J. Virology, 10:328-339 (1972) ; Van der Vliet, et al . , J. Virology, 15:348-354 (1975); and Friefeid et al . , Virology, 124:380-389 (1983) ; Englehardt, et al . , Proc.Nat. Acad. Sci., Vol. 91, pgs. 6196-6200 (June 1994) ; Yang, et al . , Nature Genetics. Vol. 7, pgs 362-369 (July 1994) .
  • Such a vector in a preferred embodiment, is constructed first by constructing, according to standard techniques, a shuttle plasmid which contains, beginning at the 5' end, the "critical left end elements," which include an adenoviral 5' ITR, an adenoviral encapsidation signal, and an Ela enhancer sequence; a promoter (which may be an adenoviral promoter or a foreign promoter) ; a multiple cloning site (which may be as hereinabove described) ; a poly A signal; and a DNA segment which corresponds to a segment of the adenoviral genome .
  • the vector also may contain a tripartite leader sequence.
  • the DNA segment corresponding to the adenoviral genome serves as a substrate for homologous recombination with a modified or mutated adenovirus, and such sequence may encompass, for example, a segment of the adenovirus 5 genome no longer than from base 3329 to base 6246 of the genome.
  • the plasmid may also include a selectable marker and an origin of replication.
  • the origin of replication may be a bacterial origin of replication.
  • Representative examples of such shuttle plasmids include pAvS6, shown in Figure 4. A desired DNA sequence encoding a clotting factor may then be inserted into the multiple cloning site to produce a plasmid vector.
  • This construct is then used to produce an adenoviral vector.
  • Homologous recombination is effected with a modified or mutated adenovirus in which at least the majority of the El and E3 adenoviral DNA sequences have been deleted.
  • Such homologous recombination may be effected through co- transfection of the plasmid vector and the modified adenovirus into a helper cell line, such as 293 cells, by CaPO ⁇ precipitation.
  • a recombinant adenoviral vector is formed that includes DNA sequences derived from the shuttle plasmid between the Not I site and the homologous recombination fragment, and DNA derived from the El and E3 deleted adenovirus between the homologous recombination fragment and the 3' ITR.
  • the homologous recombination fragment overlaps with nucleotides 3329 to 6246 of the adenovirus 5 (ATCC VR-5) genome.
  • a vector which includes an adenoviral 5' ITR, an adenoviral encapsidation signal; an Ela enhancer sequence; a promoter; at least one DNA sequence encoding a therapeutic agent; a poly A signal; adenoviral DNA free of at least the majority of the El and E3 adenoviral DNA sequences; and an adenoviral 3' ITR.
  • the vector also may include a tripartite leader sequence. This vector may then be transfected into a helper cell line, such as the 293 helper cell line (ATCC No.
  • CRL1573 which will include the Ela and Elb DNA sequences, which are necessary for viral replication, and to generate infectious adenoviral particles. Transfection may take place by electroporation, calcium phosphate precipitation, microinjection, or through proteoliposomes.
  • the vectors hereinabove described may include a multiple cloning site to facilitate the insertion of the at least one DNA sequence encoding a therapeutic agent into the cloning vector.
  • the multiple cloning site includes "rare" restriction enzyme sites; i.e., sites which are found in eukaryotic genes at a frequency of from about one in every 10,000 to about one in every 100,000 base pairs.
  • An appropriate vector in accordance with the present invention is thus formed by cutting the cloning vector by standard techniques at appropriate restriction sites in the multiple cloning site, and then ligating the DNA sequence encoding a therapeutic agent into the cloning vector.
  • the adenoviral vector includes at least one DNA sequence encoding at least one therapeutic agent.
  • therapeutic is used in a generic sense and includes treating agents, prophylactic agents, and replacement agents.
  • DNA sequences encoding therapeutic agents which may be placed into the adenoviral vector include, but are not limited to, DNA sequences encoding tumor necrosis factor
  • TNF tumor necrosinogen- ⁇ r
  • genes encoding interferons such as Interferon- ⁇ , Interferon- ⁇ , and Interferon- ⁇
  • genes encoding interleukins such as IL-1, IL-l ⁇ , and Interleukins 2 through 14
  • genes encoding GM-CSF genes encoding adenosine deaminase, or ADA
  • genes encoding antioxidants such as Mn- SOD, catalase, CuZnSOD, extracellular superoxide dismutase, and glutathione reductase
  • genes which encode cellular growth factors such as lymphokines, which are growth factors for lymphocytes
  • genes encoding growth factors such as epithelial growth factor (EGF) and keratinocyte growth factor (KGF)
  • the DNA sequence encoding a therapeutic agent is under the control of a suitable promoter.
  • suitable promoters which may be employed include, but are not limited to, adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the Rous Sarcoma Virus (RSV) promoter; inducible promoters, such as the MMTV promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; and the ApoAI promoter.
  • CMV cytomegalovirus
  • RSV Rous Sarcoma Virus
  • inducible promoters such as the MMTV promoter, the metallothionein promoter
  • heat shock promoters such as the albumin promoter
  • the albumin promoter and the ApoAI promoter.
  • the DNA sequence encoding a therapeutic agent may be under the control of its native promoter. It is to be understood, however, that
  • Immunosuppressive agents which may be employed include those which prevent: (i) a humoral (antibody) response against the adenoviral vector; (ii) a cellular immune response, such as, for example, a T-cell response to cells containing the adenoviral vector; or (iii) a non-specific inflammatory responses against the vector and against cells containing the vector.
  • a humoral and/or T-cell and/or non-specific inflammatory response against the vector, and/or cells containing the vector administration of the immunosuppressive agent permits effective re-administration of the vector in order to produce a therapeutic effect in the host.
  • the immunosuppressive agent is an immunosuppressive agent which prevents a humoral antibody response against the adenoviral vector.
  • the immunosuppressive agent is one that prevents or suppresses a cellular or non-specific inflammatory response.
  • Host immune responses to in vivo adenovirus vector administration vary in relation to (i) the dose of vector; (ii) the route of administration; (iii? the level of replication (if any occurs) ; (iv) the nature of the transgene contained in the recombinant vector; (v) the genetic and physiological characteristics of the host; and (vi) the existence and level of pre-existing immune responses to previously administered adenovirus vectors.
  • host responses are dependent on the dose of vector administered.
  • the magnitude of specific host responses is dependent on the route of vector administration.
  • intravenous administration will yield a higher host antibody response than that of an equivalent amount of vector given via the respiratory route.
  • the diverse host responses to adenovirus vectors occur due to separate inflammatory and immune effector mechanisms, although most, if not all, of these distinct molecular mechanisms are connected and significantly interdependent.
  • humoral antibody formation is very dependent on certain T-helper lymphocyte support.
  • some cell-mediated cellular toxicity is dependent on antibody formation, e.g., opsonized macrophage cell killing.
  • the two principal host responses affecting the duration of transgene expression are the inflammatory response and the cellular immune response.
  • Inflammation is one of the first host responses that occurs following vector administration. Cytokine release is very likely involved in the subsequent influx of inflammatory cells. Such cytokines likely include IL-1, IL-6, IL-8, and TNF .
  • CTL responses directed towards the transduced cells are believed to be important in reducing the duration of transgene expression. It is believed that the CTL are directed against low level adenovirus gene expression by the cells, which induces the CTL.
  • the principal host response affecting the ability to administer adenovirus vectors repeatedly to a host is the humoral antibody response. It develops to adenovirus O 96/12406 PCIYUS95/13253 administered by a variety of routes, including oral, intravenous, intraperitoneal, and intrapulmonary. In general, the level of antibody response achieved is very dependent on the dose of vector administered. The antibody response is also dependent on the route of vector administration. Intravenous vector administration results in higher antibody levels than pulmonary administration for a given dose of vector. In contrast, wild type adenovirus elicits high antibody levels irrespective of the amount of virus given due to virus replication in vivo. The ability to repeat successfully adenovirus vector administration is inversely correlated with the level of circulating anti- adenovirus vector antibody present .
  • Pharmacologic modulation of host immune responses to adenovirus vectors involves the use of anti-inflammatory agents, celllular immune modifiers, and humoral antibody immune modifiers.
  • Anti-inflammatory agents include steroids, cyclophosphamide, and azothiophrine.
  • Steroids have potent anti-inflammatory properties. Applicants have shown that steroids, such as dexamethasone, given parenterally prolong the duration of transgene expression following in vivo administration of vector via the lung route. Steroids also block the function of lymphocytes. Thus, dexamethasone reduces the CTL responses observed after pulmonary vector administration. Dexamethasone also blocks, at least in part, the host antibody response to adenovirus vector administration.
  • Antibodies directed at cellular components of the immune system reduce cellular immune response.
  • anti T- cell receptor antibody such as, for example anti-CD4 and anti-CD3 antibodies
  • CTLA4 immunoglobulin is another example.
  • Anti- CD4 antibody is directed against the T-helper lymphocytes and reduces their function.
  • Other agents directed primarily at the cellular immune response include cyclosporins such as cyclosporin A; rapamycin binding protein ligands such as FK506; and steroids such as dexamethasone.
  • Agents which affect humoral antibody responses are generally directed at antibody producing B lymphocytes (B- cells) or at the T-cells which are responsible for inducing B-cell antibody production to high levels.
  • deoxyspergualin and DSG mean deoxyspergualin or DSG and derivatives or analogues thereof, such as salts of deoxyspergualin, including but not limited to, trihydrochlorides thereof, and any other analogues which have immunosuppressive activity.
  • deoxyspergualin and DSG mean deoxyspergualin or DSG and derivatives or analogues thereof, such as salts of deoxyspergualin, including but not limited to, trihydrochlorides thereof, and any other analogues which have immunosuppressive activity.
  • Such compounds are described further in U.S. Patent Nos. 4,525,299; 4,847,299; 5,162,581; and 5,196,453.
  • the immunosuppressive agent which prevents a humoral antibody response is a steroid.
  • Steroids which may be employed include, but are not limited to, dexamethasone, and any adrenocortical hormones, such as, for example corticosteroids; hydrocortisone; prednisolone; and methyiprednisolone.
  • the immunosuppressive agent which prevents a humoral antibody response is a cyclosporin, such as, for example, cyclosporin A.
  • Other immunosuppressive agents which prevent a humoral antibody response and which may be employed include, but are not limited to, azathioprine; cyclophosphamide; brequinar; leflunomide; mycophenolate mofetil; anti-CD40 antibody; anti-CD40 ligand antibody; cyclophosphamine; rapamycin; anti-CD4 antibody; CTLA-4 immunoglobulin; Interleukin -12; Interfer ⁇ n -7; rapamycin binding protein (FEBP) ligands, such as, for example, FK506, as described in Bierer, et al .
  • FEBP rapamycin binding protein
  • Applicants have found that, when compounds which prevent, suppress, or eliminate humoral immune responses to foreign antigens (such as, for example, deoxyspergualin, cyclophosphamide, brequinar, leflunomide, mycophenolate, mofetil, anti-CD40 antibody, or anti-CD40 ligand antibody) are administered at a short time prior to, and/or during, and/or for a short time after adenoviral vector administration, to a host, such compounds prevent the production of anti-adenoviral neutralizing antibodies in the host. The prevention of the production of such neutralizing antibodies enables the efficient re-administration of the adenoviral vector to the host .
  • foreign antigens such as, for example, deoxyspergualin, cyclophosphamide, brequinar, leflunomide, mycophenolate, mofetil, anti-CD40 antibody, or anti-CD40 ligand antibody
  • an immunosuppressive agent may prevent more than one of the immune responses hereinabove described. It also is to be understood, however, that the scope of the present invention is not intended to be limited to any specific immunosuppressive agents .
  • a combination of immunosuppressive agents may be employed.
  • the adenoviral vector and immunosuppressive agent in general, are administered concurrently in an amount effective to produce a therapeutic effect in the host while preventing an immune response against the vector or against cells transduced with the vector.
  • concurrently means that the administration of the adenoviral vector and administration of the immunosuppressive agent are begun at approximately the same time, i.e., within a brief time frame of each other, and the administration of the adenoviral vector and the administration of the immunosuppressive agent are parts of a unitary course of treatment.
  • the immunosuppressive agent is administered at approximately the same time the adenoviral vector is administered, i.e., the administration of the immunosuppressive agent is begun at a short time (for example, about 24 hours) before, or during, or at a short time (e.g., 24 hours) after the administration of the adenoviral vector.
  • the immunosuppressive agent is administered according to standard dosage schedules established for that agent, and for a period of time which in general does not exceed 14 days, and preferably does not exceed 11 days, and more preferably does not exceed 8 days.
  • long-term administration of the immunosuppressive agent is not required for enabling repeated administration of the adenovirus.
  • the course of administration of the adenoviral vector and immunosuppressive agent is discontinued for a period of time.
  • the period of time between courses of administration of the adenoviral vector and the immunosuppressive agent, and the number of courses of administration of the adenoviral vector and immunosuppressive agent is dependent upon a variety of factors, including the age, weight, and sex of the patient, the disease or disorder being treated, and the severity of the disease or disorder being treated.
  • the adenoviral vector may be administered, at each administration, in an amount of from 1 plaque forming unit to about IO 1"1 plaque forming units, preferably from about 10* plaque forming units to about 10 1 plaque forming units, more preferably from about 10 8 to about 10 10 plague forming units per kg.
  • the host may be a human or non-human animal host.
  • the adenoviral vector may be administered systemically or topically.
  • systemic administration include, but are not limited to, intravenous administration (such as for example, portal vein injection or peripheral vein injection) , intramuscular administration, intraperitoneai administration, intranasal administration, or encapsulated oral administration.
  • the immunosuppressive agent is administered in an amount effective to produce a desired immunosuppressive effect in the host.
  • the immunosuppressive agent may be administered, at each administration, in an amount of from about 1 mg/kg to about 15 mg/kg, when dexamethasone is employed, or at the dose equivalents for other steroids.
  • deoxyspergualin When deoxyspergualin is employed, the deoxyspergualin may be administered in an amount of from about 1 mg/kg to about 33 mg/kg, preferably from about 3 mg/kg to about 7 mg/kg.
  • the cyclophophamide may be administered in an amount of from about 5 mg/kg to about 300 mg/kg, preferably from about 50 mg/kg to about 100 mg/kg.
  • the adenoviral vector particles and the immunosuppressive agent each may be administered in combination with a pharmaceutically acceptable carrier suitable for administration to a patient.
  • the carrier may be a liquid carrier such as, for example, a saline solution.
  • the adenoviral vector particles also may be administered in combination with a solid carrier, such as, for example, microcarrier beads, or a sustained drug delivery material, such as, for example, a polyol .
  • Cells which may be transduced by the adenoviral particles include, but are not limited to, lung, airway, or alveolar epithelial cells; primary cells, such as primary nucleated blood cells, such as leukocytes, granul ⁇ cytes, monocytes, macrophages, lymphocytes (including T-lymphocytes and B-lymphocytes) , totipotent stem cells, and tumor infiltrating lymphocytes (TIL cells) ; bone marrow cells; endothelial cells; activated endothelial cells; epithelial cells; keratinocytes; stem cells; hepatocytes, including hepatocyte precursor cells; fibroblasts; mesenchymal cells; mesothelial cells; parenchymal cells; vascular smooth muscle cells; brain cells and other neural cells; gut enterocytes; gut stem cells; and myoblasts.
  • primary cells such as primary nucleated blood cells, such as leukocytes, granul ⁇ cytes, monocyte
  • the adenoviral particles may be targeted to blood cells, whereby such adenoviral vector particles infect the blood cells with a gene which directly or indirectly enhances the therapeutic effects of the blood cells.
  • the gene carried by the blood cells can be any gene which allows the blood cells to exert a therapeutic effect that it would not ordinarily have, such as a gene encoding a clotting factor useful in the treatment of hemophilia.
  • the gene can encode one or more products having therapeutic effects.
  • suitable genes include those that encode the CFTR gene; cytokines such as TNF, interleukins (interleukins 1-14), interferons (or, ⁇ , -interferons) , T- cell receptor proteins and Fc receptors for antigen-binding domains of antibodies, such as immunoglobulins.
  • suitable genes include genes encoding soluble CD4 which is used in the treatment of AIDS and genes encoding a- antitrypsin, which is useful in the treatment of emphysema caused by ⁇ -antitrypsin deficiency.
  • the transduced cells are useful in the treatment of a variety of diseases including but not limited to, cystic fibrosis, adenosine deaminase deficiency, sickle cell anemia, thalassemia, hemophilia, diabetes, or-antitrypsin deficiency, brain disorders such as Alzheimer's disease, phenylketonuria and other illnesses such as growth disorders and heart diseases, for example, those caused by alterations in the way cholesterol is metabolized and defects of the immune system.
  • diseases including but not limited to, cystic fibrosis, adenosine deaminase deficiency, sickle cell anemia, thalassemia, hemophilia, diabetes, or-antitrypsin deficiency
  • brain disorders such as Alzheimer's disease, phenylketonuria and other illnesses such as growth disorders and heart diseases, for example, those caused by alterations in the way cholesterol is metabolized and defects of the immune system.
  • the adenoviral vector particles may transduce liver cells, and such adenoviral vector particles may include gene(s) encoding polypeptides or proteins which are useful in prevention and therapy of an acquired or an inherited defect in hepatocyte (liver) function. For example, they can be used to correct an inherited deficiency of the low density lipoprotein (LDL) receptor, and/or to correct an inherited deficiency of ornithine transcarbamylase (OTC) , which results in congenital hyperammonemia.
  • LDL low density lipoprotein
  • OTC ornithine transcarbamylase
  • the adenoviral particles may transduce liver cells, whereby the adenoviral particles include a gene encoding a therapeutic agent employed to treat acquired infectious diseases, such as diseases resulting from viral infection.
  • the infectious adenoviral particles may be employed to treat viral hepatitis, particularly hepatitis B or non-A non-B hepatitis .
  • an infectious adenoviral particle containing a gene encoding an antisense gene could be employed to infect liver cells to inhibit viral replication .
  • the infectious adenoviral particle which includes a vector including a structural hepatitis gene in the reverse or opposite orientation , would be introduced into liver cells , resulting in production in the infected liver cells of an anti -sense gene capable of inactivating the hepatitis virus or its RNA transcripts .
  • the liver cells may be infected with an infectious adenoviral particle which includes a gene which encodes a protein, such as , for example , ⁇ - interferon , which may confer resistance to the hepat itis virus .
  • the vector particles also may be employed in treating Hodgkin ' s lymphoma .
  • An infectious adenoviral vector particle may be targeted to neoplastic cells of Hodgkin' s lymphoma .
  • the adenoviral vector particle also includes a negat ive selective marker or " suicide gene , such as the Herpes Simplex thymidine kinase gene .
  • suicide gene such as the Herpes Simplex thymidine kinase gene .
  • the adenovirus may be administered in vivo to a patient , whereby the virus infects neoplastic cells of Hodgkin' s lymphoma .
  • the patient is given an interaction agent such as gancyclovir or acyclovir , whereby the neoplastic Hodgkin ' s lymphoma cells infected with the adenovirus are killed .
  • an interaction agent such as gancyclovir or acyclovir
  • a vector may be constructed which includes the CFTR gene .
  • the vector then may be administered to the respiratory epithelium in an effective therapeutic amount for the correction of the pulmonary def icit in patients with cystic f ibrosis .
  • vectors containing functional proteins may be delivered to the respiratory epithelium in order to correct deficiencies in such proteins .
  • Such functional proteins include antioxidants, Q.-1- antitrypsin, CFTR, lung surfactant proteins, cytokines, and growth factors such as EGF and KGF, and may also include adenosine deaminase for treatment of severe combined immune deficiency, von Willebrand's factor for treatment of Christmas disease, and tf-glucuronidase for treatment of Gaucher's disease.
  • vectors including genes encoding anti-cancer agents or anti-inflammatory agents may be administered to lung cells of a patient for the treatment of lung cancer or inflammatory lung disease.
  • the adenoviral construction shuttle plasmid pAvS6 was constructed in several steps using standard cloning techniques including polymerase chain reaction based cloning techniques. First, the 2913 bp Bglll, Hindlll fragment was removed from Ad-dl327 and inserted as a blunt fragment into the Xhol site of pBluescript II KS- (Stratagen , La Jolla, CA) ( Figure 1) .
  • Ad-dl327 is identical to adenovirus 5 except that an Xbal fragment including bases 28591 to 30474 (or map units 78.5 to 84.7) of the Adenovirus 5 genome, and which is located in the E3 region, has been deleted.
  • the E3 deletion in Ad-dl327 is similar to the E3 deletion in Ad-dl324, which is described in Thimmappaya et al . , Cell , 31:543 (1983) .
  • the complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Rockville, Maryland, U.S.A. under accession number VR-5.
  • Ad-dl327 was constructed by routine methods from Adenovirus 5 (Ad5) . The method is outlined briefly as follows and previously described by Jones and Shenk, Cell 13:181-188, (1978) .
  • Ad5 DNA is isolated by proteolytic digestion of the virion and partially cleaved with Xba I restriction endonuclease. The Xba I fragments are then reassembled by ligation as a mixture of fragments. This results in some ligated genomes with a sequence similar to Ad5, except excluding sequences 28591 bp to 30474 bp.
  • This DNA is then transfected into suitable cells (e . g. KB cells, HeLa cells, 293 cells) and overlaid with soft agar to allow plaque formation. Individual plaques are then isolated, amplified, and screened for the absence of the 1878 bp E3 region Xba I fragment .
  • This plasmid was designated PH . ( Figure 1) .
  • the ITR, encapsidation signal, Rous Sarcoma Virus promoter, the adenoviral tripartite leader (TPL) sequence and linking sequences were assembled as a block using PCR amplification ( Figure 2) .
  • the ITR and encapsidation signal (sequences 1-392 of Ad-dl327 [identical to sequences from Ad5, Genbank accession #M73260] incorporated herein by reference) were amplified (amplification 1) together from Ad-dl327 using primers containing NotI or Ascl restriction sites.
  • the Rous Sarcoma Virus LTR promoter was amplified (amplification 2) from the plasmid pRC/RSV (sequences 209 to 605; Invitrogen, San Diego, CA) using primers containing an Ascl site and an Sfil site. DNA products from amplifications 1 and 2 were joined using the "overlap" PCR method (amplification 3) (Horton et al . , BioTechniques, 8:528-535 (1990)) with only the NotI primer and the Sfil primer. Complementarity between the Ascl- containing end of each initial DNA amplification product from reactions 1 and 2 allowed joining of these two pieces during amplification.
  • the TPL was amplified (amplification 4) (sequences 6049 to 9730 of Ad-dl327 [identical to similar sequences from Ad5, Genbank accession #M73260] ) from cDNA made from mRNA isolated from 293 cells (ATCC Accession No. CRL 1573) infected for 16 hrs. with Ad-dl327 using primers containing Sfil and Xbal sites respectively. DNA fragments from amplification reactions 3 and 4 were then joined using PCR (amplification 5) with the NotI and Xbal primers, thus creating the complete gene block.
  • amplification 4 sequences 6049 to 9730 of Ad-dl327 [identical to similar sequences from Ad5, Genbank accession #M73260]
  • Ad-dl327 using primers containing Sfil and Xbal sites respectively.
  • DNA fragments from amplification reactions 3 and 4 were then joined using PCR (amplification 5) with the NotI and Xbal primers, thus creating the complete gene block.
  • the ITR-encapsidation signal-TPL fragment was then purified, cleaved with NotI and Xbal and inserted into the NotI, Xbal cleaved PHR plasmid.
  • This plasmid was designated pAvS6A " and the orientation was such that the NotI site of the fragment was next to the T7 RNA polymerase site ( Figure 3) .
  • the SV40 early polyA signal was removed from SV40 DNA as an Hpal-BamHI fragment, treated with T4 DNA polymerase and inserted into the Sail site of the plasmid pAvS ⁇ a- ( Figure 3) to create pAvS6 ( Figures 3 and 4) .
  • AvlLucl ( Figure 7) (Yei et al . , Gene Therapy, Vol . 1 , pgs . 192-200 (1994) ) is an adenoviral reporter vector identical in genomic organization and sequence to AvlCf2, except that it expresses the firefly luciferase gene (Genbank Accession No. M15077) .
  • the firefly luciferase gene was obtained from pGEM-luc ( Figure 8 - Promega) .
  • pGEM-luc was digested with StuI and Hindlll in order to splice out the firefly luciferase gene.
  • the firefly luciferase gene was inserted into the EcoRV site of pAvS6 so that the 5' end of the firefly luciferase coding sequence was closest to the Adenovirus 5 tripartite leader.
  • the resulting plasmid, pAvS6-Lucl ( Figure 9) was linearized with Kpnl and recombined with the large (35 kb) Clal fragment of Ad-dl327 as hereinabove described. Clonal isolates then were identified as hereinabove described.
  • Both viral vectors were propagated, purified by double- banding in CsCl gradients, and titered in 293 cells as described in Rosenfeld et al . , Cell , 65:143-155 (1992) .
  • Example 2 Adenoviral-mediated gene transfer with concurrent intermittent steroid administration
  • Cotton rats (weight approximately 150g) were divided into four groups with 9 rats in each group.
  • AvlCf2 was administered by intranasal inhalation (Yei et al . , Human Gene Therapy, Vol. 5, pgs. 731-744 (1994)) to the lungs of cotton rats at a low dose (10 s pfu) or at a high dose (10 10 pfu) , either with or without coadministration of dexamethasone by intraperitoneal injection in an amount of 2 mg/kg daily, beginning 1 day prior to and continuing for 10 days after administration of the vector.
  • a control group of rats was given PBS instead of AvlCf2 , either with or without coadministration of dexamethasone as hereinabove described.
  • mice At 3 days and at 42 days after vector administration, 3 rats from each group were evaluated for host responses to the AvlCf2 vector. Evaluations of host responses included pulmonary histopathology appearance, total lung lavage cellularity, lung lavage anti-adenovirus antibody production, and cytotoxic T-lymphocyte (CTL) response.
  • CTL cytotoxic T-lymphocyte
  • Figure 10a is a section of the lung of a control rat that did not receive adenovirus and instead received PBS.
  • Figure 10B is a section of the lung of a rat which received AvlCf2 without immunosuppression therapy.
  • Figure IOC is a section of the lung of a rat which received AvlCf2 with daily administration of dexamethasone. All sections have been magnified 100 times. As shown in Figures 10A, 10B, and IOC, there was less pulmonary parenchymal inflammation in the rat which received adenovirus and immunosuppressive therapy as compared with the control rat and the rat infected with adenovirus, but did not receive immunosuppression therapy.
  • Lung lavage fluid was collected by lavaging the lung with 4.0 ml of PBS, and the total number of cells determined by counting in a hemocytometer, or the cells were evaluated in cytocentrifuge preparations for the percentage of neutrophils by light microscopy.
  • Figure 11A is a graph of the lung lavage cell count from rats infected with AvlCf2 three days after infection, as compared with control rats which received PBS. The control rats either received dexamethasone or did not receive dexamethasone.
  • Figure 11B is a graph of the lung lavage cell count from rats infected with AvlCf2 at 42 days after infection, as compared with control rats which received PBS. The rats either received dexamethasone or did not receive im unosuppressant therapy.
  • dexamethasone significantly reduced the non-specific host cellular inflammatory responses (represented by total lung lavage cellularity) at three days after vector administration, which is the peak of inflammation.
  • Lung lavage anti-adenovirus production was measured by an ELISA assay carried out as follows.
  • Blocking agent then was added to the background wells.
  • 50 ⁇ l of antibody samples i.e., lung lavage samples prepared as hereinabove described
  • 50 al of negative control samples of serum from an uninfected cotton rat were added to another set of coated wells at the same serial dilutions.
  • the plate the was incubated for 2 hours at room temperature, and 300 ⁇ l of 0.05% Tween 20/PBS then was added.
  • the plate was incubated O 96/12406 PCMJS95/13253 for 5 minutes at room temperature, emptied, and 300 ⁇ l of 0.05% Tween 20/PBS again was added.
  • the plate then was washed twice with double distilled H0 or PBS.
  • Peroxidase-labeled goat anti-hamster IgG (lO ⁇ g/lO ⁇ l) was diluted with 10 ml BSA and PBS to make a working solution of 1 mg/ml concentration. (1:1,000 dilution) . 100 ⁇ l of this solution then was added to each well, and the plate was incubated at room temperature for 2 hours . The plate then was washed five times with 300 ⁇ l of 0.01% Tween 20/PBS. The plate then was emptied and dried.
  • TMB tetramethyl benzidine
  • Sensitizer cells were prepared by infecting cotton rat lung fibroblasts with Ad-dl327 at a multiplicity of infection of 100. The cells were incubated for 3 days, and checked for hexon expression by FACS. The cells then were washed with PBS/EDTA, contacted with trypsin, washed, spun, and resuspended in 1 ml RPMI medium. The cells then were irradiated with 13 Cs at 5,000 rads in order to inactivate the DNA.
  • Spleens then were isolated from uninfected (control) rats and adenovirus-infected rats 42 days after infection.
  • the spleens were kept in sterile HBSS and ice. 10 ml of HBSS then was injected into each spleen with a 25/27 gauge needle. The spleen was mashed, and filtered with a cell strainer into a 50 ml tube. The volume then was brought to 40 ml in RPMI plus 10% FCS. The tube was spun at 1,500 rpm for 10 minutes. Red blood cells then were lysed by adding 2.5 ml of ACK lysis buffer, and the liquid was swirled for less than 1 minute. The volume was brought up to 50 ml with RPMI-10.
  • the tube then was spun again at 1,500 rpm for 10 minutes.
  • the cell pellet then was resuspended, and cells were counted at a 1:10 dilution.
  • the splenocytes then were plated with the sensitizer cells at a ratio of splenocytes to sensitizer cells of 4:1 in RPMI.
  • the splenocytes and sensitizer cells were incubated at 37°C in the presence of 20-50 units/mi of Interleukin-2. Interleukin-2 was added daily for 5 to 6 days .
  • Target cells were prepared by infecting 3X10 6 cotton rat lung fibroblasts with Ad-dl327 at a multiplicity of infection of 100 for 1 hour. Culture medium is added to the cells, and 3i Cr in an amount greater than 50 ⁇ Ci is added for 18 hours.
  • Target cells are harvested by washing the cotton rat lung fibroblasts with EDTA/PBS, followed by trypsinization. The cells then were washed, spun, resuspended in 5 ml culture medium, and counted. The cells were resuspended to 10 s cells/ml and 10 4 cells/0.1 ml well were used for the CTL assay.
  • Effector cells i.e., the combination of splenocytes and sensitizing cells (also sometimes referred to as Es cells) were spun at 1,500 rpm for 10 minutes at 4°C. The cells were resuspended in 2 ml of HBSS-10, loaded onto 7 ml Ficoll Hypaque, and spun at 1,500 rpm for 10 minutes. The top portion (4 ml) was harvested, and 5 ml of culture medium was added. This material was spun, the cell pellet was saved, and resuspended in 1 ml of culture medium. The effector cells were counted by mixing 50 ⁇ l of effector cells with 50 ⁇ l Trypan blue.
  • effector cells then were added to wells containing IO "1 target cells, at effector:target (E:T) ratios of 3.125, 6.25, 12.5, 25, 50, and 100.
  • the cells then were spun at 500 rpm for 5 minutes.
  • the cells then were incubated at 37°C for 4 hours.
  • the cells then were spun, and 100 ⁇ l of supernatant was analyzed for 3i Cr release with a WALLAC gamma counter.
  • the average results for CTL response in splenocytes taken from infected rats (with and without dexamethasone treatment) , and from two unmfected control rats, are shown in Figure 13.
  • the efficiency of repeat adenovirus-mediated gene transfer was significantly higher in the rats which received AvlCf2 and dexamethasone than those which did not receive dexamethasone at the time of the first adenoviral administration (11,786 ⁇ 3523 lu vs. 622 ⁇ 192 lu, respectively) .
  • the efficiency of gene transfer from AvlLucl also was higher in the control group which initially received PBS in conjunction with dexamethasone.
  • Example 3 Suppression of humoral immune response with DSG or high dose cyclophosphamide, permitting effective repeat administration of an adenoviral vector
  • This example describes the intravenous administration of the adenoviral vectors AvlLacZ4 and AvlH9F2 to C57BL/6 male mice (Harlan Sprague Dawley, Indianapolis, Indiana) at 5 to 6 weeks of age at the start of the experiment.
  • AviLacZ4 is an adenoviral vector which includes a nuclear targeted B- galactosidase gene, (lacZ) and is described in PCT application No. W095/09654, published April 13, 1995.
  • AvlH9F2 is constructed from a derivative of the adenoviral shuttle plasmid vector pAvlH9FR ( Figure 15) , which includes human Factor IX DNA, and is described in PCT application No. W094/29471, published December 22, 1994.
  • the shuttle plasmid pAvlH9FR was digested with the restriction enzyme Sfil, the DNA ends were made blunt using T4 DNA Polymerase, and the DNA molecule was recircularized by ligation. Competent DH5 cells were transformed and ampicillin-resistant clones were amplified and screened by restriction enzyme digestion of minipre'p DNA. A positive clone was identified and the resulting shuttle plasmid was referred to as pAvS17H9F.
  • AvlH9F2 has a base pair deletion at the beginning of the tripartite leader, or TPL, which effectively changes the ATG into a CTG.
  • TPL tripartite leader
  • mice were immunosuppressed with 33 mg/kg of deoxyspergualin DSG (Nippon Kayaku Co. LTD, Tokyo, Japan) , delivered intraperitoneally (ip) , once daily, beginning the day before vector administration and continuing for a total of eight days.
  • ip intraperitoneally
  • SUBS ⁇ rUTE SHEET (RULE 26) was reconstituted with 3.8 ml of injection grade water to yield a 25 mg/ml solution, which was aliquoted and frozen at -20°C. Each day, immediately before immunosuppression, an aliquot was thawed at room temperature and 0.7 ml was mixed with 6.3 ml of Hank's Balanced Salt Solution (HBSS) to yield a 2.5 mg/ml solution. The mice were weighed once, immediately prior to the first dose of DSG. Six mice received 1 x 10 8 pfu of AvllacZ4 via tail vein injection on the second day of the immunosuppression regimen and 1 x 10* pfu of AvlH9F2 five weeks later. Another six mice received only AvlH9F2, five weeks after immunosuppression. Three mice were immunosuppressed, but received no adenoviral vector.
  • HBSS Hank's Balanced Salt Solution
  • mice Six mice were immunosuppressed with a low dose (100 mg/kg) cyclophosphamide (Sigma) and fifteen mice were treated with a high dose (300 mg/kg) .
  • the animals received a single ip injection of cyclophosphamide one day before administration of adenoviral vector. All six mice which were treated with a low dose of cyclophosphamide also received 1 x 10 s pfu of AvllacZ4 the day after cyclophosphamide and 1 x 10 8 pfu of AvlH9F2 five weeks later.
  • mice immunosuppressed with a high dose of cyclophosphamide received a 1 x 10* pfu of AvllacZ4 the next day and 1 x 10 3 pfu of AvlH9F2 five weeks later. Another six did not receive AvllacZ4 but did receive AvlH9F2. Finally, three mice were immunosuppressed, but received no adenoviral vector.
  • mice Twelve mice were immunosuppressed with 5 mg/kg dexamethasone (American Reagent Laboratories, Inc., Shirley, New York) , delivered ip, once daily, beginning the day before vector administration and continuing for a total of eight days. Six of these mice receive 1 x 10* pfu of AvllacZ4 on the second day of dexamethasone treatment and 1 x 10* pfu of AvlH9F2 five weeks later. Five immunosuppressed mice received only AvlH9F2 and one mouse received no vector. Five weeks after administration of AvllacZ4, but prior to administration of AvlH9F2, plasma was prepared from some mice and analyzed for antiadenovirus neutralizing antibodies.
  • dexamethasone American Reagent Laboratories, Inc., Shirley, New York
  • mice which receive AvlLacZ4 without immunosuppression were detected in the plasma of mice which receive AvlLacZ4 without immunosuppression, however, mice which received vector and either DSG or high dose cyclophosphamide had no detectable neutralizing antibodies. In contrast, mice immunosuppressed with low dose cyclophosphamide or dexamethasone developed neutralizing antibodies.
  • Neutralizing antibody titers in 20 mice are given in Table I below. As indicated in Table I, D " SG is deoxyspergualin, Cy is cyclophosphamide, and Dex is dexamethasone.
  • mice immunosuppressed with a low dose of cyclophosphamide at the time of AvllacZ4 administration did not express human Factor IX after delivery of AvlH9F2 .
  • Mice treated with a high dose of cyclophosphamide , but not administered AvllacZ4 expressed an average of 8 ⁇ g/ml one week after delivery of AvlH9F2.
  • Mice treated with cyclophosphamide, but not treated with either adenoviral vector did not express human Factor IX.
  • Example 4 Suppression of humoral immune response to adenoviral vectors to enable the repeat administrations thereof This example is an elaboration and expansion of the data contained in Example 3. In this example, the following materials and methods were employed.
  • AvlLacZ4 and AvlH9F2 were described in Example 3 hereinabove.
  • AvlH9FR was made by cotransfecting 293 cells with pAvlH9FR ( Figure 15) with the large DNA fragment from Clal digested Ad dl327.
  • Recombinant adenoviral vector plaques were picked, expanded, and screened for expression of Factor IX by ELISA.
  • a positive clone was identified and amplified, thus generating the vector AvlH9FR.
  • This vector like AvlH9F2 , contains a centrally truncated first intron and the complete 5' and 3' untranslated regions from the human Factor IX gene.
  • the centrally truncated first intron and 3' untranslated region are essentially the same sequences described by Jallat, et al . , BMBO J.. Vol. 9, pgs. 3295-3301 (1990) .
  • AvlALAPH ⁇ l is an adenoviral vector which contains the B- domain deleted human Factor VIII cDNA expressed from the mouse albumin promoter, and is described in published PCT Application No. W094/29471.
  • All vector stocks contained less than 1 in IO 6 wild-type adenovirus, as determined by quantitative PCR analysis of Ela sequences.
  • Deoxyspergualin (manufactured by Nippon Kayaku Co., Ltd., Tokyo, Japan) was a gift from Bristol-Myers-Squibb, Princeton, N.J. A 100 mg vial of deoxyspergualin was reconstituted with water to a final concentration of 25 mg/ml, aliquoted, and frozen at -70°C. Frozen stocks were thawed at room temperature and diluted with Hanks Balanced Salt Solution (HBSS) prior to injection.
  • HBSS Hanks Balanced Salt Solution
  • Deoxyspergualin is an immunosuppressant currently being tested clinically in organ transplantation. It has a potent, long term effect on antigen specific B cells and has been shown to prevent effectively the production of specific antibody when co-administered with protein antigens.
  • Cyclophosphamide (Cy) was obtained from Sigma and Dissolved in HBSS.
  • mice were obtained from Harlan Sprague Dawley
  • Adenoviral vectors were administered via tail vein injection after diluting the appropriate amount of vector stock to 0.5 ml with Hanks Balanced Salt Solution
  • HBSS HBSS
  • blood was obtained from the retroorbital plexus.
  • sodium citrate was added immediately to a final concentration of 0.38% (w/v) .
  • sera samples the blood was allowed to clot. Samples were centrifuged for 5 min. in an Eppendorf Microfuge after which the plasma or serum was collected, aliquoted, and frozen.
  • Plasma levels of human Factor VIII were determined by ELISA, as described in Connelly, et al . , Human Gene Therapy. Vol. 6, pgs. 185-193 (1995) .
  • SUBS ⁇ TUTESHEET(RULE26) VIII was 3 to 6 ng/ml.
  • Mouse plasma samples were diluted 1:5 prior to the assay, therefore, the actual limit of detection was 15 to 30 ng/ml.
  • Plasma levels of human Factor IX were determined by ELISA. Asserachrom IX:Ag ELISA kits were purchased from American Bioproducts Company (Parsippany, NJ) and assays were performed according to the manufacturer's instructions. The limit of sensitivity was 1.6 ng/ml.
  • Mouse plasma or serum samples were heat inactivated at 55°C for 30 minutes and then diluted in Improved Minimal Essential Medium (Biofluids, Rockville, MD) plus 2% FBS (IMEM/2%FBS) in two-fold steps beginning at 1:2.
  • 55 ⁇ l of each sample were mixed with 10 ⁇ l of AvllacZ4 (containing 4 x IO 3 pfu) , incubated for 1 hour at 37°C and applied to nearly confluent 293 cells in 96 well plates (4 x 10 4 cells per well) . After 60 minutes in the tissue culture incubator, the virus was aspirated from each well and replaced with 150 ⁇ l of IMEM/10%FBS.
  • adenovirus vector AvllacZ4 to C57BL/6 mice via tail vein were administered.
  • the vector inoculum ranged from 1 x 10 3 pfu to 1 x 10 8 pfu in single log increments.
  • serum levels of anti-adenovirus neutralizing antibodies were determined (Fig. 18) for mice which received lxlO 5 pfu or greater of vector. A minus sign indicates that none of the mice in the cohort had detectable antibody.
  • mice which received lxlO 8 pfu of vector indicate that three of the five mice had an antibody titer of 8, while two mice had no detectable antibody.
  • three of five mice which received 1 x 10 8 pfu had a level of anti-adenovirus antibody which was sufficient to neutralize 4xl0 5 pfu of AvlLacZ4 , while two mice had undetectable levels. None of the mice which received lower doses of vector had detectable antibodies using this relatively stringent neutralization assay.
  • each mouse received 2 x 10* pfu of AvlH9FR, an adenoviral vector encoding human Factor IX.
  • the plasma levels of human Factor IX were determined by ELISA (Fig. 18) .
  • An average of approximately 2 ⁇ g/ml of Factor IX was detected in mice which received either no AvllacZ4, or up to 1 x 10 5 pfu of the first vector.
  • Factor IX was also readily detected in the mice which had received a first dose of 1 x IO 6 and 1 x 10 7 pfu, although the levels were reduced.
  • mice which received 1 x 10 8 pfu of AvllacZ4 yielded little or no human Factor IX after administration of AvlH9FR.
  • effective gene transfer and expression can be achieved with a second vector administration, provided the initial vector dose is below a certain threshold level.
  • the data indicate that for intravenous delivery in C57BL/6 mice, this value is between 10 7 and 10 8 pfu.
  • Transient immunosuppression increases the efficiency of vector re-administration.
  • C57BL/6 mice were immunosuppressed with either deoxyspergualin (DSG) , cyclophosphamide (Cy) , or dexamethasone (Dex) at the time of administration of 1 x 10 8 pfu of AvllacZ4. As shown above, this dose completely prevented an effective second delivery. Mice were injected daily with 33 mg/kg of DSG, beginning one day before vector delivery and continuing for seven more days. Dexamethasone was delivered over the same time course, at a dose of 5 mg/kg. Cyclophosphamide was administered once, the day before vector delivery, at a dose of either 100 mg/kg or 300 mg/kg. Control mice received AvllacZ4 without immunosuppression, or were immunosuppressed without initial vector delivery.
  • DSG deoxyspergualin
  • Cy cyclophosphamide
  • Dex dexamethasone
  • mice in each cohort which had been immunosuppressed with cyclophosphamide or dexamethasone were immunosuppressed again, using the same regimen as at the first vector delivery.
  • plasma levels of anti-adenovirus neutralizing antibodies were determined.
  • the mice immunosuppressed with 300 mg/kg cyclophosphamide had no detectable neutralizing antibodies, while mice immunosuppressed with 100 mg/kg cyclophosphamide or 5 mg/kg dexamethasone had a measurable response (data not shown) .
  • DSG permits effective repeat administration at a clinically relevant dose.
  • mice were immunosuppressed with 5, 10, 20, and 33 mg/kg of DSG at the time of administration of 1 x 10- pfu of AvllacZ4. Immunosuppression was started the day before vector delivery and continued for a total of 8 days. On the day of vector delivery, DSG was given after injection of the adenovirus since it is most effective when administered after antigen. (Takahara, et al . , Transplantation, Vol. 53, pgs. 914-918 (1992) ) .
  • each mouse received 1 x 10 s pfu of AvlH9F2.
  • human Factor IX plasma levels were determined by ELISA (Fig. 21) .
  • Control mice which were not pre-immunized with AvlLacZ4, expressed an average of 9 ⁇ g/ml of human Factor IX.
  • Other control mice which received AvllacZ4 but were not immunosuppressed, expressed no human Factor IX after AvlH9F2 administration.
  • the one mouse which was immunosuppressed with 33 mg/kg DSG expressed 12 ⁇ g/ml of human Factor IX.
  • mice immunosuppressed with 20 mg/kg DSG expressed an average of 3.0 ⁇ g/ml of human Factor IX, and one mouse expressed none.
  • Mice which were not immunosuppressed at the time of AvllacZ4 administration expressed no human Factor IX.
  • an i-adenovirus neutralizing antibody titers are maintained for at least ten months in mice after a single administration of vector via tail vein.
  • the long-term maintenance of titer may have been due to a low level of ongoing adenoviral backbone gene expression in transduced cells.
  • Vectors designed to reduce or eliminate backbone gene expression may elicit a weaker immune response and therefore may require less immunosuppression for successful readministration.
  • An important property of DSG is that it does not produce a general suppression of the immune system, but rather results in a selective lack of response to specific antigens presented at the time of drug treatment.
  • Cyclophosphamide administered at a dose of 300 mg/kg the day before vector injection, was also effective in blocking the humoral response and allowed a completely effective second injection with a Factor IX adenovirus vector. Furthermore, a third injection with a Factor VIII encoding vector was also completely efficacious when the previous two vector administrations were each preceded by a single dose of cyclophosphamide. Cyclophosphamide is used clinically as an anti-cancer agent m the treatment of Hodgkins disease and other leukemias. It is also employed as an immunosuppressive agent in the treatment of hemophilia patients who develop inhibitors to Factor VIII protein replacement therapy. (Aledort, Am. J. Hemat.. Vol.
  • mice While the dose used to successfully obtain readministration in mice is substantially higher than is generally used in humans, it remains to be established whether lower, clinically acceptable doses, might be effective in humans.
  • combinations of immunosuppressants would yield more potent suppression of the immune system with less toxicity.
  • cyclophosphamide may be effective at lower doses when used in combination with dexamethasone. It is also possible that the degree of immunosuppression required will depend on the dose of vector which is needed to effect therapy.
  • AvlH9F2 used in this study, 1 x 10 s pfu, yielded plasma levels of human Factor IX of 5-10 ⁇ g/ml, which is 20 to 50 times above a level that would be therapeutic in a hemophiliac.
  • Vectors such as AvlH9F2, which express high levels of transgene product and which can be administered at relatively low doses, should reduce the extent of immune stimulation and the degree of immunosuppression required.
  • Applicants have shown that effective repetitive delivery of systemically administered adenovirus vectors can be achieved with short term immunosuppression. Importantly, this can be accomplished using pharmacologic agents which are either approved for use in humans, or are in clinical testing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé de traitement d'un hôte par thérapie génique consistant à: (a) administrer concurremment à l'hôte, d'une part (i) un vecteur adénoviral incluant au moins une séquence d'ADN codant un agent thérapeutique, et d'autre part (ii) un agent immunodépresseur; (b) arrêter l'administration dudit vecteur adénoviral et dudit agent immunodépresseur; et (c) répéter au moins une fois l'administration du vecteur adénoviral et de l'agent immunodépresseur. La répétition cyclique de l'administration du vecteur adénoviral et d'un agent immunodépresseur permet la poursuite ou l'accroissement de l'expression d'au moins la séquence ADN codant l'agent thérapeutique.
EP95938753A 1994-10-19 1995-10-19 Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs Withdrawn EP0804076A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32567994A 1994-10-19 1994-10-19
US325679 1994-10-19
US47848295A 1995-06-07 1995-06-07
US478482 1995-06-07
PCT/US1995/013253 WO1996012406A1 (fr) 1994-10-19 1995-10-19 Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs

Publications (2)

Publication Number Publication Date
EP0804076A1 true EP0804076A1 (fr) 1997-11-05
EP0804076A4 EP0804076A4 (fr) 1998-10-21

Family

ID=26985040

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95938753A Withdrawn EP0804076A4 (fr) 1994-10-19 1995-10-19 Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs

Country Status (4)

Country Link
EP (1) EP0804076A4 (fr)
JP (1) JPH10507758A (fr)
CA (1) CA2200869A1 (fr)
WO (1) WO1996012406A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026285A2 (fr) * 1995-02-24 1996-08-29 The Trustees Of The University Of Pennsylvania Methodes et compositions pour l'administration de vecteurs de therapie genique
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
AU2251897A (en) * 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
IL131021A0 (en) 1997-01-29 2001-01-28 Cornell Res Foundation Inc Multiple site delivery of adenoviral vector for the induction of angiogenesis
US5985824A (en) * 1997-02-27 1999-11-16 Genzyme Corporation Methods and compositions for treating cystic fibrosis
DE19711803A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung mit 15-Deoxyspergualin
IL142069A0 (en) * 1998-09-21 2002-03-10 Genetics Inst Methods of downmodulating the immune response to therapeutic proteins
WO2000029033A2 (fr) * 1998-11-17 2000-05-25 The General Hospital Corporation Technique d'apport de vecteurs genetiques
CA2395544A1 (fr) * 1999-12-28 2001-07-05 Novartis Ag Procede de mise en oeuvre d'une expression persistante de transgenes
US20020014242A1 (en) 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
WO2003033520A2 (fr) 2001-09-24 2003-04-24 University Of Pittburgh Of The Commonwealth System Of Higher Education Vaccin anticancereux, methodes diagnostiques et reactifs
EP1944043A1 (fr) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation.
NZ532383A (en) 2001-11-21 2007-03-30 Univ Pennsylvania Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CN1893981B (zh) * 2003-12-10 2011-03-23 坎基股份有限公司 用于治疗干扰素耐药性肿瘤的方法和组合物
WO2005086922A2 (fr) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Adenovirus oncolytique dote de genes therapeutiques
ES2382775T3 (es) 2004-10-08 2012-06-13 Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services Inmunoterapia adoptiva con supervivencia de linfocitos T potenciada.
WO2007044033A2 (fr) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Récepteur non restreint par le cmh cloné de l'antigène spécifique de tumeur muc1 pour applications thérapeutiques et diagnostiques
DK2220241T3 (en) 2007-11-28 2017-01-09 Univ Pennsylvania Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof
BRPI0819774A2 (pt) 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
WO2010011994A2 (fr) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides et leurs utilisations
EP2350269B1 (fr) 2008-10-31 2015-09-09 The Trustees Of The University Of Pennsylvania Adénovirus simiens avec des proteines de capsides hexon de sadv-46 et leurs utilisations
US8846031B2 (en) 2009-05-29 2014-09-30 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
EP2643465B1 (fr) 2010-11-23 2016-05-11 The Trustees Of The University Of Pennsylvania Adénovirus simiens de la sous-famille e a1321 et ses utilisations
CA2834619A1 (fr) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Administration regulee d'immunosuppresseurs a partir de nanovecteurs synthetiques
BR112014028684A2 (pt) 2012-05-18 2017-07-25 Univ Pennsylvania subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
JP6580558B2 (ja) 2013-05-03 2019-09-25 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物
DK3010519T3 (en) 2013-06-18 2021-05-17 Dnatrix Inc Oncolytic adenovirus for use in a treatment of brain cancer
US10046064B2 (en) * 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
JP2019519501A (ja) * 2016-05-12 2019-07-11 ブライアン ピー． ハンリーＢｒｉａｎ Ｐ． ＨＡＮＬＥＹ ヒトおよび動物における体細胞の大部分へのｃｒｉｓｐｒおよび他の遺伝子治療薬の安全な送達
KR20240015743A (ko) * 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
EP3592389A1 (fr) 2017-03-11 2020-01-15 Selecta Biosciences, Inc. Procédés et compositions associés à un traitement combiné avec anti-inflammatoires et nanovecteurs synthétiques comprenant un immunosuppresseur
EP3488851A1 (fr) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Thérapies immunoablatives
CN114126666A (zh) * 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2181673T3 (es) * 1991-05-01 2003-03-01 Jackson H M Found Military Med Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9612406A1 *

Also Published As

Publication number Publication date
EP0804076A4 (fr) 1998-10-21
CA2200869A1 (fr) 1996-05-02
WO1996012406A1 (fr) 1996-05-02
JPH10507758A (ja) 1998-07-28

Similar Documents

Publication Publication Date Title
WO1996012406A1 (fr) Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
WO1996012406A9 (fr) Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
EP0710288B1 (fr) Vecteurs adenoviraux pour le traitement de l'hemophilie
Tao et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver
Xiao et al. Adeno-associated virus as a vector for liver-directed gene therapy
US5756086A (en) Adenoviruses having modified fiber proteins
AU704391B2 (en) Improved adenovirus and methods of use thereof
US5552309A (en) Use of polyols for improving the introduction of genetic material into cells
Brown et al. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A
AU697022B2 (en) Methods and compositions for administering gene therapy vectors
Geest et al. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone
Varnavski et al. Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity
NZ330553A (en) Recombinase-mediated generation of adenoviral vectors where all adenoviral genes of all regions E1 to E4 and L1 to L5 of the adenoviral genome are eliminated
WO1998032842A1 (fr) Adenovirus comprenant des proteines d'hexon modifiees
JP2004500880A (ja) 肝臓特異的な遺伝子発現カセット、及びその使用法
NZ300387A (en) Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
WO1997039776A9 (fr) Therapie genique reposant sur l'administration conjointe et repetee d'adenovirus et d'agents immunosuppresseurs
WO1997039776A1 (fr) Therapie genique reposant sur l'administration conjointe et repetee d'adenovirus et d'agents immunosuppresseurs
Oka et al. Recent advances in liver-directed gene therapy: implications for the treatment of dyslipidemia
US6372208B1 (en) Method of reducing an immune response to a recombinant virus
US6251957B1 (en) Method of reducing an immune response to a recombinant virus
WO2005027711A2 (fr) Vecteurs d'adenovirus a capside modifiee et methodes d'utilisation
US6132989A (en) Methods and compositions for enhanced stability of non-adenoviral DNA
NZ527645A (en) Method of enhancing delivery of a therapeutic nucleic acid
Podevin et al. In-vivo retroviral gene transfer to the liver is cancelled by an immune response against the corrected cells. Can it be avoided?

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970417

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980904

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020501